NL-OMON20400尚未招募不适用
Recovered COVID-19 patients: blood sampling
ISA Pharmaceuticals B.V.0 个研究点目标入组 14 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 14
研究概览
简要总结
ot applicable
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Inclusion criteria for both recovered COVID-19 patients and healthy participants
- •1.Participant must sign the study informed consent form prior to any study-mandated procedure indicating that he or she understands the purpose, procedures and potential risks, and is willing to participate in the study;
- •2.Participant is male or female and between 18 and 65 years of age, inclusive, at the time of enrollment;
- •3.Participant is willing and able to complete the study procedures;
- •4.Participant has a primary care physician at the time of enrollment;
- •5.Participant is not taking any immunosuppressive medication or other immunomodulating agents (including investigational drugs) for at least 3 weeks prior to study blood sampling.
- •Inclusion criteria for recovered COVID-19 patients only
- •1.Participant reports a previous positive diagnostic test result for SARS-CoV-2 infection (serological testing or viral RNA detection by PCR testing);
- •2.Participant had clinical symptoms of COVID-19 (including, but not limited to: cough, fever, shortness of breath, sudden onset of anosmia, ageusia or dysgeusia). The diagnosis of COVID-19 must be the most plausible cause of the reported symptoms, as deemed by the study physician;
- •3.Participant has recovered from COVID-19 for at least three weeks prior to study blood sampling (residual symptoms such as, but not limited to, fatigue and reduced exercise tolerance - that would not jeopardize study endpoints - are allowed at the investigator’s discretion).
- •Inclusion criteria for healthy participants only
- •1.Participant is generally healthy in the investigator’s clinical judgment, as determined by medical history evaluation, including no clinically significant disorder, condition, infection or disease that would interfere with the study evaluation, procedures or completion.
排除标准
- •Exclusion criteria for both recovered COVID-19 patients and healthy participants
- •1.Participant with a whole blood donation or loss of >500 ml within 21 days before study blood sampling;
- •2.Any known factor, condition, or disease that might interfere with compliance, study conduct or interpretation of the results, as deemed by the investigator.
- •Exclusion criteria for healthy participants only
- •1.Participant reports a previous positive diagnostic test result for SARS-CoV-2 infection (serological testing or viral RNA detection by PCR testing);
- •2.Participant developed clinically overt symptoms of COVID-19 following close contact with a proven SARS-CoV-2 positive patient, but was not tested (e.g. due to limited test capacity and regulations at that time);
- •3.Participant who is currently working, or has worked in an occupation with a high risk of exposure to SARS-CoV-2 (e.g. health care worker).
研究者
相似试验
已完成
不适用
Acquiring Convalescent Specimens for COVID-19 AntibodiesCOVID-19Corona Virus InfectionCoronavirus InfectionNCT04342195Columbia University15
已完成
不适用
COVID-19 Immunity AssessmentCOVID-19NCT05080231DxTerity Diagnostics662
已完成
2 期
Convalescent Plasma in the Treatment of COVID 19Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)COVIDCoronavirusNCT04343261Trinity Health Of New England48
进行中（未招募）
不适用
Analysis of Coronavirus Disease 19 (COVID-19) Convalescent PlasmaAsymptomatic COVID-19 Infection Laboratory-ConfirmedSymptomatic COVID-19 Infection Laboratory-ConfirmedNCT04497779City of Hope Medical Center95
已完成
不适用
Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19COVID-19NCT04360278National Institutes of Health Clinical Center (CC)258